Want to see AU:ACR full AI Analyst Report?
Top Page
Acrux
(Sydney:ACR)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.01
â–˛(10.00% Upside)
Action:Upgraded
Date:08/27/26
The score is held back primarily by persistent losses and a weaker balance sheet (compressed equity and higher leverage), despite improved 2026 revenue and a positive turn in cash flow. Technical signals add downside risk, with the stock trading below key moving averages and negative momentum indicators. Valuation is difficult to assess due to negative earnings and no dividend yield data.
Positive Factors
2026 Revenue Rebound
The sharp 2026 revenue recovery indicates renewed commercial activity after prior declines and provides a stronger base for future operating leverage. If revenue remains elevated, it could support improved cost absorption, reinvestment, and progress toward sustainable profitability over the next several quarters.
Negative Factors
Persistent Unprofitability
Recurring net, EBIT, and EBITDA losses show that the current operating model has not yet produced sustainable profitability. Continued losses can consume financial resources, limit self-funded investment, and make future performance dependent on maintaining revenue gains and controlling costs.
Read all positive and negative factors
Positive Factors
Negative Factors
2026 Revenue Rebound
The sharp 2026 revenue recovery indicates renewed commercial activity after prior declines and provides a stronger base for future operating leverage. If revenue remains elevated, it could support improved cost absorption, reinvestment, and progress toward sustainable profitability over the next several quarters.
Read all positive factors
Acrux (ACR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$6.67M
Dividend Yield9.09%
Average Volume (3M)715.88K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth290.25%
EPS Growth92.05%
CountryAU
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding606,344,500
10 Day Avg. Volume100,243
30 Day Avg. Volume715,875
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.46
Price to Sales (P/S)1.09
P/FCF Ratio4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$14.20M
Acrux Business Overview & Revenue Model
Company Description
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other internatio...
How the Company Makes Money
null...
Acrux Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
52
Neutral
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.64M | 1.19M | 5.09M | 8.43M | 1.72M |
| Gross Profit | 4.21M | 1.19M | 1.13M | 1.95M | -4.65M |
| EBITDA | -1.70M | -5.17M | -8.06M | -2.79M | -12.29M |
| Net Income | -604.00K | -5.95M | -5.80M | -764.00K | -9.83M |
Balance Sheet | |||||
| Total Assets | 6.82M | 7.22M | 8.96M | 14.30M | 15.27M |
| Cash, Cash Equivalents and Short-Term Investments | 1.71M | 863.00K | 2.94M | 6.23M | 5.83M |
| Total Debt | 2.52M | 3.63M | 3.70M | 2.35M | 2.08M |
| Total Liabilities | 5.36M | 6.20M | 5.69M | 5.60M | 6.18M |
| Stockholders Equity | 1.47M | 1.02M | 3.28M | 8.70M | 9.09M |
Cash Flow | |||||
| Free Cash Flow | 1.02M | -5.48M | -4.58M | 584.00K | -9.28M |
| Operating Cash Flow | 1.02M | -5.47M | -4.30M | 703.00K | -8.82M |
| Investing Cash Flow | 0.00 | -5.00K | -276.00K | -119.00K | -465.00K |
| Financing Cash Flow | -178.00K | 3.39M | 1.29M | -183.00K | -155.00K |
Acrux Technical Analysis
Neutral
0.01
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Negative
57.18
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACR, the sentiment is Neutral. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.18 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ACR.
Acrux Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$410.99M | 11.99 | 13.00% | 0.61% | -1.05% | -6.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$13.54M | -2.74 | -164.96% | ― | -4.24% | 33.39% | |
49 Neutral | AU$360.18M | -44.15 | -42.35% | ― | 145.32% | 25.75% | |
47 Neutral | AU$57.47M | -0.65 | -118.74% | ― | 499.47% | 31.20% | |
46 Neutral | AU$6.67M | -7.86 | -45.29% | 9.09% | 290.25% | 92.05% | |
43 Neutral | AU$5.44M | -1.02 | -52.04% | ― | 32.22% | -26.53% |
* Healthcare Sector Average
AU:ACR
Acrux
0.01
>-0.01
-21.43%
AU:CUV
Clinuvel Pharmaceuticals
8.15
-2.72
-25.05%
AU:SPL
Starpharma Holdings Limited
0.76
0.62
476.34%
AU:TRP
Tissue Repair Ltd
0.09
-0.19
-67.86%
AU:CMB
Regeneus Ltd.
0.46
-0.05
-10.68%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.12
-85.00%
Acrux Corporate Events
Acrux Director Boosts Equity Stake via Loan-Funded Share Issue
Sep 2, 2026
Acrux Limited has reported a change in director Geoffrey Brooke’s interests, reflecting an issue of 2,400,000 new ordinary shares to him supported by a limited recourse, interest-free loan. Following the transaction, Brooke’s direct an...
Acrux Discloses New Equity Award to Director Under Loan Structure
Sep 2, 2026
Acrux Ltd has disclosed a change in director John Warmbrunn’s interests in company securities, in line with ASX listing rules and Australian corporate law. The notice underscores the company’s adherence to governance and reporting stan...
Acrux Boosts Director Equity via Loan-Funded Share Issue
Sep 2, 2026
Acrux Ltd has disclosed a change in director Tim Oldham’s interests in the company’s securities, reflecting adjustments to his direct and indirect holdings. The notice details his existing stake through related entities and personal ho...
Acrux Boosts Director Equity Stake Through Loan-Supported Share Issue
Sep 2, 2026
Acrux Ltd has disclosed a change in director interests, detailing an update to the shareholdings of board member Don Brumley. The company, an ASX-listed pharmaceutical developer specialising in drug delivery technologies, continues to use equity-b...
Acrux Seeks ASX Quotation for Employee Incentive Shares
Sep 2, 2026
Acrux Limited has applied for quotation on the ASX of 716,679 ordinary fully paid shares, with an issue date of 3 September 2026. The shares relate to securities previously issued under an employee incentive scheme, for which transfer restrictions...
Acrux Seeks ASX Quotation for 15.75 Million New Shares
Sep 2, 2026
Acrux Limited, an ASX-listed pharmaceutical developer, issues ordinary fully paid shares as part of its capital structure and relies on employee incentive schemes to support talent retention and align staff with shareholder outcomes. The company&#...
Acrux Updates Market With 2026 Governance and Compliance Filings
Aug 26, 2026
Acrux Limited has released its Appendix 4G and Corporate Governance Statement for the financial year ended 30 June 2026, as authorised by its board. The disclosures outline the company’s governance framework, compliance with ASX principles a...
Acrux to Brief Investors on Women’s Health Hormone Therapy Strategy
Aug 14, 2026
Acrux Limited will host an investor webinar on 17 August 2026 to update shareholders and the market on its progress in executing a development strategy centred on women’s health and hormone replacement therapies. CEO and Managing Director Jo...
Acrux Seeks ASX Quotation for 200,000 Employee Scheme Shares
Aug 13, 2026
Acrux Limited has applied to the ASX for quotation of 200,000 ordinary fully paid shares, with the securities scheduled for issue on 13 August 2026. The new quoted shares arise from securities previously issued under an employee incentive scheme, ...
Acrux Reports Lapse of 110,000 Performance Rights
Aug 13, 2026
Acrux Limited has notified the market of a change to its issued capital following the lapse of 110,000 performance rights. The rights ceased on 13 August 2026 after the conditions attached to these securities were not met or became incapable of be...
Acrux Highlights Female Testosterone Strategy at Bioshares Biotech Summit
Aug 5, 2026
Acrux Limited announced that CEO and Managing Director John Warmbrunn is presenting at Bioshares’ 20th Biotech Summit. The investor presentation, which accompanies the announcement, places a clear emphasis on female testosterone, underscorin...
Acrux Completes $1.6m Share Placement and Confirms Regulatory Compliance
Jul 29, 2026
Acrux has completed a two‑tranche share placement raising approximately $1.6 million before costs, issuing over 168 million new ordinary shares to institutional and professional investors at 0.95 cents per share. The company also confirmed t...
Acrux Seeks ASX Quotation for 65.8 Million Additional Shares
Jul 29, 2026
Acrux Limited has applied to the Australian Securities Exchange for quotation of 65,768,908 ordinary fully paid shares under its existing ticker ACR. The move reflects the company’s continued use of equity markets to support its capital stru...
Acrux Director Increases Shareholding Through Exercise of Vested Rights
Jul 23, 2026
Acrux Limited has reported a change in the securities holdings of director Ross Dobinson, in line with ASX listing rule 3.19A.2 and corporate disclosure obligations. The filing underscores the company’s adherence to governance standards by p...
Acrux Seeks ASX Quotation for Employee Incentive Shares
Jul 23, 2026
Acrux Limited, listed on the Australian Securities Exchange under the code ACR, utilises ordinary fully paid shares as part of its capital structure. It also operates an employee incentive scheme that issues equity to staff, supporting alignment b...
Acrux Seeks ASX Quotation for New Shares Issued Under Employee Scheme
Jun 25, 2026
Acrux Limited has applied for quotation on the ASX of 495,976 new ordinary fully paid shares, to be issued on June 25, 2026. These shares have been issued under an employee incentive scheme and will be eligible for quotation despite not being subj...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.